The purpose of this study is to evaluate the safety, tolerability, drug levels of BMS-986369 following administration of single ascending oral doses (SAD) in healthy adult participants. The study will also explore the effect of high-fat meal on the single-dose drug level of BMS-986369 in healthy adult participants.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
68
Specified dose on specified days
Local Institution - 0001
Miami, Florida, United States
Maximum observed plasma concentration (Cmax)
Time frame: Day 1
Time of maximum observed plasma concentration (Tmax)
Time frame: Day 1
Area under the plasma concentration-time curve, from time zero extrapolated to infinite time (AUC(INF))
Time frame: Up to 336 hours after dose administration
Number of participants with Adverse Events (AEs)
Time frame: From the date of having consented until 30 days after completion of study treatment
Number of participants with vital sign abnormalities
Time frame: Up to Day 15
Number of participants with clinical laboratory abnormalities
Time frame: Up to Day 15
Number of participants with electrocardiogram (ECG) abnormalities
Time frame: Up to Day 15
Effect of BMS-986369 on ECG parameters - Part 1
Time frame: Up to 72 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.